Participants
advanced/metastatic, tumour
DISEASE, MALIGNANCIES, TUMOUR, ONCOLOGY, APPENDIX
Eligible patients were adults (≥18 years of age) with histologically confirmed malignancies that have progressed to the advanced/metastatic stage, with measurable disease per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1, and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.As outlined in Supplementary Fig. Prior treatment varied by tumour type, but all patients were required to have received standard of care for the treatment of their disease (Supplementary Fig. Key exclusion criteria were platinum-resistant/refractory EOC and prior treatment with therapies targeting PD-1, PD-L1, or PARP. Full eligibility criteria are provided in the Supplementary Appendix.